BLA 125147 · Amgen
Vectibix
Panitumumab · Iv (Infusion) · Epidermal Growth Factor Receptor Antagonist
NovelAccelerated approvalLast checked: Nov 20, 2026Latest source record: Jan 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Sep 27, 2006
Approved uses
6
Original approval plus efficacy supplements
Registered trials
282
32 Phase 3, 41 recruiting
FAERS reports
16,106
14,116 serious, 2,738 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DERMATOLOGIC TOXICITY Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: DERMATOLOGIC TOXICITY See full prescribing information for complete boxed warning . Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy. ( 2.3 , 5.1 , 6.1 )
What it is approved for
From the label in effect Jun 23, 2026.
Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of: Adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal Cancer (mCRC)*: In combination with FOLFOX for first-line treatment. ( 1 , 14.2 ) As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. ( 1 , 14.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)* In combination with sotorasib, for the treatment of adult patients with KRAS G12C- mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1 ) *Limitations of Use: Vectibix is not indicated for the treatment of patients with RAS -mutant mCRC unless used in combination with sotorasib in KRAS G12C-mutated mCRC. Vectibix is not indicated for the treatment of patients with mCRC for whom RAS mutation status is unknown ( 1 , 2.1 , 5.2 , 12.1 , 14.3 ). Metastatic Colorectal Cancer (mCRC) RAS Wild-Type mCRC Vectibix is indicated for the treatment of adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) metastatic colorectal cancer (mCRC) [see Dosage and Administration (2.1) ] : As first-line therapy in combination with FOLFOX [see Clinical Studies (14.2) ] . As monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy [see Clinical Studies (14.1) ] . KRAS G12C -mutated mCRC Vectibix, in combination with sotorasib, is indicated for the treatment of adult patients with KRAS G12C- mutated mCRC, as determined by...
Mechanism: The EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases, including EGFR, HER2, HER3, and HER4. EGFR is constitutively expressed in normal epithelial tissues, including the skin and hair follicle. EGFR is overexpressed in certain human cancers, including colon and rectum cancers. Interaction of EGFR with its normal ligands (e.g., EGF, transforming growth factor-alpha) leads to phosphorylation and activation of a series of intracellular proteins, which in turn regulate transcription of genes involved with cellular growth and survival,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 16, 2025 Supplement 213 · Efficacy · priority review LabelLetter
- Jun 29, 2017 Supplement 207 · Efficacy LabelLetter
- May 23, 2014 Supplement 186 · Efficacy LabelLetter
- May 23, 2014 Supplement 108 · Efficacy LabelLetter
- Jun 23, 2008 Supplement 26 · Efficacy LetterLabel
- Sep 27, 2006 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalLabelReviewLetter
3 products under this application
- VECTIBIX · PANITUMUMAB 20ML/400MG · INJECTABLE, IV (INFUSION) · Prescription
- VECTIBIX · PANITUMUMAB 5ML/100MG · INJECTABLE, IV (INFUSION) · Prescription
- VECTIBIX · PANITUMUMAB 10ML/200MG · INJECTABLE, IV (INFUSION) · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Panitumumab" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to FluorouracilPivotal-lookingCompleted
University of LeedsAcademic, hospital or other
NCT00389870 · 1,198 participants · Start Dec 2006
Drug: panitumumab; cyclosporine and 1 more · For: Colorectal Cancer
Sites: Bournemouth, United Kingdom; Brighton, United Kingdom; Bristol, United Kingdom · 33 sites in all
- Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy AlonePivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00339183 · 1,186 participants · Start Jun 30, 2006 · Primary completion Apr 1, 2009
Drug: Panitumumab; FOLFIRI · For: Metastatic Colorectal Cancer
- PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine EfficacyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00364013 · 1,183 participants · Start Aug 1, 2006 · Primary completion Aug 1, 2009
Drug: Panitumumab; FOLFOX regimen · For: Metastatic Colorectal Cancer
- PACCE: Panitumumab Advanced Colorectal Cancer Evaluation StudyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00115765 · 1,053 participants · Start Jun 1, 2005 · Primary completion May 31, 2007
Drug: Oxaliplatin Based Chemotherapy; Panitumumab and 2 more · For: Colorectal Cancer
- Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by SurgeryPivotal-lookingStatus unknown
University of BirminghamAcademic, hospital or other
NCT00647530 · 1,053 participants · Start May 15, 2008 · Primary completion Dec 23, 2016
Drug: panitumumab; capecitabine and 2 more · For: Colorectal Cancer
Sites: Birmingham, United Kingdom; Gateshead, United Kingdom; Huddersfield, West Yorks, United Kingdom · 10 sites in all
- ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal CancerPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01001377 · 1,010 participants · Start Feb 2, 2010 · Primary completion Feb 5, 2013
Drug: Cetuximab; Panitumumab · For: Metastatic Colorectal Cancer
Sites: Stockton, California; Boynton Beach, Florida; Wichita, Kansas · 152 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash1,979
- diarrhoea1,649
- dermatitis acneiform1,069
- death1,060
- neutropenia963
- skin toxicity934
- nausea863
- colorectal cancer metastatic861
- hypomagnesaemia849
- disease progression749
- neuropathy peripheral749
- off label use743
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 3 |
| 2006 | 26 |
| 2007 | 315 |
| 2008 | 326 |
| 2009 | 334 |
| 2010 | 359 |
| 2011 | 601 |
| 2012 | 524 |
| 2013 | 489 |
| 2014 | 625 |
| 2015 | 709 |
| 2016 | 962 |
| 2017 | 965 |
| 2018 | 1,176 |
| 2019 | 1,241 |
| 2020 | 1,015 |
| 2021 | 891 |
| 2022 | 956 |
| 2023 | 1,169 |
| 2024 | 1,050 |
| 2025 | 948 |
| 2026 | 1,422 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vectibix (Panitumumab)
2024 spending
$4.2M
Beneficiaries
68
303 claims
Per beneficiary
$61,449
$328.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,135,862 |
| 2021 | $2,235,138 |
| 2022 | $2,283,143 |
| 2023 | $3,629,418 |
| 2024 | $4,178,524 |
Part B: Vectibix (Panitumumab) · HCPCS J9303
2024 spending
$137M
Beneficiaries
2,636
18,403 claims
Per beneficiary
$51,946
2024 ASP limit $154.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $100,556,796 |
| 2021 | $100,065,716 |
| 2022 | $118,238,478 |
| 2023 | $132,133,362 |
| 2024 | $136,930,119 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.
Fakih MG, Salvatore L, Esaki T, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Multicenter Study
- Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial.
Morton D, Seymour M, Magill L, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Watanabe J, Muro K, Shitara K, et al. · JAMA 2023 · Clinical Trial, Phase III, Comparative Study
- Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY, Oliner KS, Siena S, et al. · N Engl J Med 2013 · Comparative Study, Randomized Controlled Trial
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Corcoran RB, André T, Atreya CE, et al. · Cancer Discov 2018 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
Lacouture ME, Mitchell EP, Piperdi B, et al. · J Clin Oncol 2010 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.